查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1587472

北美獸醫腫瘤學市場規模、佔有率和趨勢分析報告：2025-2030 年按動物、治療、癌症、國家和細分市場進行的預測

North America Veterinary Oncology Market Size, Share & Trends Analysis Report By Animal (Canine, Feline), By Therapy (Radiotherapy, Surgery, Chemotherapy), By Cancer (Skin Cancer, Lymphoma), By Country, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

北美獸醫腫瘤學市場成長與趨勢：

Grand View Research, Inc.最新報告顯示，到2030年，北美獸用腫瘤市場規模預計將達到12.2億美元，2025年至2030年複合年成長率為10.70%。

該市場的推動因素包括寵物癌症發病率的上升、調查各種癌症治療的安全性和有效性的獸醫臨床試驗的數量以及寵物保險普及率的上升。此外，針對伴同性動物癌症標靶治療的研究和開發的策略性舉措不斷增加正在推動市場成長。例如，2023 年 7 月，Ardent Animal Health 與 FidoCure 合作，利用後者的基因組測試和精準醫療平台，擴大獸醫腫瘤學創新的應用範圍。

在 COVID-19 期間，由於面臨多項挑戰，市場成長緩慢。這場流行病影響了獸醫癌症研究和開發工作以及關鍵寵物藥品的後勤供應。獲得獸醫護理的機會也受到限制。根據世界動物健康協會2020年報告，對寵物飼主的一項調查發現，在許多國家，獸醫服務因寵物獸醫護理的延誤或遺漏而受到阻礙。但這場大流行也加速了數位科技的採用，以加強護理。 2020 年 3 月，PetCure Oncology 升級了其遠距醫療選項，讓寵物家庭和轉診獸醫與公司經過董事會認證的放射腫瘤科醫生進行遠端連接。

由於存在多個從小到大的市場參與者，市場分散且競爭激烈。參與者正在積極部署策略性舉措來獲得市場佔有率。例如，2022年1月，Decra從Anivive Life Sciences收購了Labeldia-CA1（Vergynexol片劑）在美國的銷售、行銷和支援權。 2022年6月，勃林格殷格翰國際股份有限公司與生物製藥公司CarthroniX建立研究夥伴關係，開發犬隻癌症領域的小分子療法。 2023 年 4 月，Torigen Pharmaceuticals 將與獸醫管理集團 (VMG) 合作，向 VMG 的 2,000 多家會員診所網路提供該公司的實驗性自製產品和服務。

北美獸醫腫瘤學市場報告亮點

  • 從動物類型來看，2024 年犬類市場佔據主導地位，佔銷售佔有率超過 86.25%。同時，貓科動物預計在預測期內將以超過 12.38% 的複合年成長率成長最快。這是由夥伴關係和研究合作的增加所推動的，以加速可靠的獸醫癌症治療的開發和商業化。例如，2022 年 10 月，Ardent Animal Health 完成了一項用於治療狗癌症的新型查核點抑制劑的授權合約。
  • 從治療方法來看，手術領域佔據市場主導地位，2024年銷售量超過36.09%。預計免疫治療領域在預測期內將以最快的複合年成長率成長。
  • 按癌症類型分類，皮膚癌領域佔據市場主導地位，2024年收益佔有率將超過39.01%。預計其他細分市場在預測期內將以最快的複合年成長率成長。
  • 依國家分類，2024年美國獸用腫瘤市場佔北美地區最大佔有率，達89.02%。美國的成長歸功於關鍵參與者的存在和市場參與者的策略舉措。 2023 年 4 月，Torigen Pharmaceuticals 在美國康乃狄克州法明頓開設了新的生產設施和總部。

目錄

第1章調查方法和範圍

第 2 章執行摘要

第 3 章北美獸醫腫瘤學市場變數、趨勢與範圍

  • 市場體系展望
    • 母市場展望
    • 相關/輔助市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
    • 市場機會分析
    • 市場問題分析
  • 北美獸醫腫瘤學市場分析工具
    • 波特的分析
    • PESTEL分析
  • COVID-19 分析
  • 主要國家的寵物數量估計

第4章北美獸醫腫瘤學市場：動物估計與趨勢分析

  • 細分儀表板
  • 北美獸醫腫瘤市場波動分析
  • 2018-2030年北美獸醫腫瘤學市場規模與趨勢分析（按動物）
  • 狗
  • 貓
  • 馬

第5章北美獸醫腫瘤市場：治療估計與趨勢分析

  • 細分儀表板
  • 北美獸醫腫瘤市場波動分析
  • 2018-2030 年北美獸醫腫瘤市場規模與趨勢分析（依治療）
  • 放射治療
    • 立體定位放射治療
    • 常規放射線治療
  • 外科手術
  • 化療
  • 免疫療法
  • 其他治療

第6章北美獸醫腫瘤市場：癌症類型估計與趨勢分析

  • 細分儀表板
  • 北美獸醫腫瘤市場波動分析
  • 2018-2030年北美獸醫腫瘤學市場規模與趨勢分析（依癌症類型）
  • 皮膚癌
  • 淋巴瘤
  • 肉瘤
  • 其他

第7章北美獸醫腫瘤市場：區域估計和趨勢分析

  • 區域儀表板
  • 2018-2030年市場規模及預測及趨勢分析
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥

第8章 競爭格局

  • 市場參與企業分類
  • 企業市場分析/熱圖分析
  • 2023年企業市場佔有率評估分析
  • 策略規劃
    • 併購
    • 夥伴關係與協作
    • 其他
  • 公司簡介
    • Elanco
    • Boehringer Ingelheim International GmbH.
    • Zoetis
    • PetCure Oncology
    • Accuray Incorporated
    • Varian Medical Systems, Inc.
    • Elekta AB.
    • Karyopharm Therapeutics, Inc.
    • Virbac.
    • Merck &Co., Inc.
    • Dechra Pharmaceuticals PLC
    • NovaVive Inc.
    • Ardent Animal Health, LLC（A BreakthrU Company）.

第 9 章 要點

Product Code: GVR-4-68040-138-7

North America Veterinary Oncology Market Growth & Trends:

The North America veterinary oncology market size is expected to reach USD 1.22 billion by 2030, expanding at a CAGR of 10.70% from 2025 to 2030, according to a new report by Grand View Research, Inc. The market is driven by the rising incidence of cancer in pets, the number of veterinary clinical trials investigating the safety and effectiveness of various oncologic therapies, and the increasing penetration of pet insurance. Moreover, increasing strategic initiatives for R&D of targeted therapies for cancer in companion animals is boosting market growth. For instance, in July 2023, Ardent Animal Health partnered with FidoCure to expand access to oncology innovation in veterinary medicine by leveraging the latter's genomic testing and precision medicine platform.

During COVID-19, the market witnessed dampened growth owing to several challenges. The pandemic impacted veterinary cancer research & development efforts and the logistics supply of crucial pet pharmaceuticals. It also limited access to veterinary care. According to the Global Animal Health Association's 2020 report, pet owners in a study said that in many countries, veterinarian services were hampered by delayed or skipped care for pets. The pandemic, however, also accelerated the adoption of digital technologies to enhance care. In March 2020, PetCure Oncology upgraded its Telehealth options to enable pet families and referring veterinarians to remotely connect with its board-certified radiation oncologists.

The market is fragmented and competitive due to the presence of several small-to-large market players. Players are actively involved in deploying strategic initiatives to gain market share. For instance, in January 2022, Dechra acquired the rights to sell, market, and support Laverdia-CA1 (verdinexor tablets) in the U.S. from Anivive Lifesciences, Inc. In June 2022, Boehringer Ingelheim International GmbH entered into a research partnership with CarthroniX, a biopharma company, to develop small molecule therapeutics in canine oncology. In April 2023, Torigen Pharmaceuticals partnered with Veterinary Management Groups (VMG) to provide their experimental autologous prescription products and services to the latter's more than 2,000 member clinics network.

North America Veterinary Oncology Market Report Highlights:

  • Based on animal type, the canine segment dominated the market in 2024 with a revenue share of over 86.25%. The feline segment, on the other hand, is projected to grow at the fastest CAGR of over 12.38% over the forecast period. This is attributed to the increasing partnerships and collaborations to further the development and launch of reliable veterinary cancer therapies. In October 2022, Ardent Animal Health, for example, completed a license agreement for a novel checkpoint inhibitor for canine cancer treatment
  • In terms of therapy, the surgery segment dominated the market in 2024 with a revenue share of over 36.09%. Immunotherapy segment is estimated to grow at the fastest CAGR over the forecast period.
  • Based on cancer type, the skin cancers segment dominated the market in 2024 with a revenue share of over 39.01%. The others segment is expected to grow at the fastest CAGR over the forecast period.
  • Based on country, The veterinary oncology market in the U.S. held the largest share of 89.02% in the North American region in 2024 The growth in the U.S. is attributed to the presence of key players and strategic initiatives by market players. In April 2023, Torigen Pharmaceuticals opened a new production facility and headquarters in Farmington, Connecticut, U.S.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
    • 1.1.1. Scope
    • 1.1.2. Estimates And Forecast Timeline
  • 1.2. Market Definitions
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased Database
    • 1.4.2. GVR's Internal Database
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
    • 1.6.1. Commodity flow analysis
    • 1.6.2. Global Market: CAGR Calculation
  • 1.7. Research Scope and Assumptions
    • 1.7.1. List of Secondary Sources
    • 1.7.2. List of Primary Sources
    • 1.7.3. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. North America Veterinary Oncology Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Drivers Analysis
      • 3.2.1.1. Increasing Prevalence Of Cancer In Pets
      • 3.2.1.2. Increasing R&D In Pet Cancer Therapy
      • 3.2.1.3. Growing Focus On Animal Safety
      • 3.2.1.4. Growing Uptake Of Pet Insurance
      • 3.2.1.5. Technological Advancements In Pet Cancer Treatment
      • 3.2.1.6. Increase In Pet Population
    • 3.2.2. Market Restraints Analysis
      • 3.2.2.1. High cost of treatment
      • 3.2.2.2. Adverse effects associated with therapies
      • 3.2.2.3. Complex Regulatory Guidelines
    • 3.2.3. Market Opportunity Analysis
    • 3.2.4. Market Challenges Analysis
  • 3.3. North America Veterinary Oncology Market Analysis Tools
    • 3.3.1. Porter's Analysis
      • 3.3.1.1. Bargaining power of the suppliers
      • 3.3.1.2. Bargaining power of the buyers
      • 3.3.1.3. Threats of substitution
      • 3.3.1.4. Threats from new entrants
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Economic and Social Landscape
      • 3.3.2.3. Technological landscape
      • 3.3.2.4. Environmental Landscape
      • 3.3.2.5. Legal landscape
  • 3.4. Covid-19 Analysis
  • 3.5. Estimated Pet Population, by key countries

Chapter 4. North America Veterinary Oncology Market: Animal Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. North America Veterinary Oncology Market Movement Analysis
  • 4.3. North America Veterinary Oncology Market Size & Trend Analysis, by Animal, 2018 to 2030 (USD Million)
  • 4.4. Canine
    • 4.4.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
  • 4.5. Feline
    • 4.5.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
  • 4.6. Equine
    • 4.6.1. Market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 5. North America Veterinary Oncology Market: Therapy Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. North America Veterinary Oncology Market Movement Analysis
  • 5.3. North America Veterinary Oncology Market Size & Trend Analysis, by Therapy, 2018 to 2030 (USD Million)
  • 5.4. Radiotherapy
    • 5.4.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.4.2. Stereotactic Radiation Therapy
      • 5.4.2.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
      • 5.4.2.2. LINAC
        • 5.4.2.2.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
      • 5.4.2.3. Other Type
        • 5.4.2.3.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.4.3. Conventional Radiation Therapy
      • 5.4.3.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.5. Surgery
    • 5.5.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.6. Chemotherapy
    • 5.6.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.7. Immunotherapy
    • 5.7.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.8. Other Therapies
    • 5.8.1. Market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 6. North America Veterinary Oncology Market: Cancer Type Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. North America Veterinary Oncology Market Movement Analysis
  • 6.3. North America Veterinary Oncology Market Size & Trend Analysis, by Cancer type, 2018 to 2030 (USD Million)
  • 6.4. Skin Cancer
    • 6.4.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.5. Lymphomas
    • 6.5.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.6. Sarcomas
    • 6.6.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.7. Others
    • 6.7.1. Market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 7. North America Veterinary Oncology Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Dashboard
  • 7.2. Market Size & Forecasts and Trend Analysis, 2018 to 2030
  • 7.3. North America
    • 7.3.1. Market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.3.2. U.S.
      • 7.3.2.1. Key Country Dynamics
      • 7.3.2.2. Competitive Insights
      • 7.3.2.3. U.S. Veterinary Oncology Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.3. Canada
      • 7.3.3.1. Key Country Dynamics
      • 7.3.3.2. Competitive Insights
      • 7.3.3.3. Canada Veterinary Oncology Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.4. Mexico
      • 7.3.4.1. Key Country Dynamics
      • 7.3.4.2. Competitive Insights
      • 7.3.4.3. Canada Veterinary Oncology Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Market Participant Categorization
  • 8.2. Company Market Position Analysis/ Heat Map Analysis
  • 8.3. Estimated Company Market Share Analysis, 2023
  • 8.4. Strategy Mapping
    • 8.4.1. Mergers & Acquisitions
    • 8.4.2. Partnerships & Collaborations
    • 8.4.3. Others
  • 8.5. Company Profiles
    • 8.5.1. Elanco
      • 8.5.1.1. Participant's Overview
      • 8.5.1.2. Financial Performance
      • 8.5.1.3. Product Benchmarking
      • 8.5.1.4. Strategic Initiatives
    • 8.5.2. Boehringer Ingelheim International GmbH.
      • 8.5.2.1. Participant's Overview
      • 8.5.2.2. Financial Performance
      • 8.5.2.3. Product Benchmarking
      • 8.5.2.4. Strategic Initiatives
    • 8.5.3. Zoetis
      • 8.5.3.1. Participant's Overview
      • 8.5.3.2. Financial Performance
      • 8.5.3.3. Product Benchmarking
      • 8.5.3.4. Strategic Initiatives
    • 8.5.4. PetCure Oncology
      • 8.5.4.1. Participant's Overview
      • 8.5.4.2. Financial Performance
      • 8.5.4.3. Product Benchmarking
      • 8.5.4.4. Strategic Initiatives
    • 8.5.5. Accuray Incorporated
      • 8.5.5.1. Participant's Overview
      • 8.5.5.2. Financial Performance
      • 8.5.5.3. Product Benchmarking
      • 8.5.5.4. Strategic Initiatives
    • 8.5.6. Varian Medical Systems, Inc.
      • 8.5.6.1. Participant's Overview
      • 8.5.6.2. Financial Performance
      • 8.5.6.3. Product Benchmarking
      • 8.5.6.4. Strategic Initiatives
    • 8.5.7. Elekta AB.
      • 8.5.7.1. Participant's Overview
      • 8.5.7.2. Financial Performance
      • 8.5.7.3. Product Benchmarking
      • 8.5.7.4. Strategic Initiatives
    • 8.5.8. Karyopharm Therapeutics, Inc.
      • 8.5.8.1. Participant's Overview
      • 8.5.8.2. Financial Performance
      • 8.5.8.3. Product Benchmarking
      • 8.5.8.4. Strategic Initiatives
    • 8.5.9. Virbac.
      • 8.5.9.1. Participant's Overview
      • 8.5.9.2. Financial Performance
      • 8.5.9.3. Product Benchmarking
      • 8.5.9.4. Strategic Initiatives
    • 8.5.10. Merck & Co., Inc.
      • 8.5.10.1. Participant's Overview
      • 8.5.10.2. Financial Performance
      • 8.5.10.3. Product Benchmarking
      • 8.5.10.4. Strategic Initiatives
    • 8.5.11. Dechra Pharmaceuticals PLC
      • 8.5.11.1. Participant's Overview
      • 8.5.11.2. Financial Performance
      • 8.5.11.3. Product Benchmarking
      • 8.5.11.4. Strategic Initiatives
    • 8.5.12. NovaVive Inc.
      • 8.5.12.1. Participant's Overview
      • 8.5.12.2. Financial Performance
      • 8.5.12.3. Product Benchmarking
      • 8.5.12.4. Strategic Initiatives
    • 8.5.13. Ardent Animal Health, LLC (A BreakthrU Company).
      • 8.5.13.1. Participant's Overview
      • 8.5.13.2. Financial Performance
      • 8.5.13.3. Product Benchmarking
      • 8.5.13.4. Strategic Initiatives

Chapter 9. Key Takeaways

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 North America Veterinary Oncology Market, by Animal, 2018 - 2030 (USD Million)
  • Table 4 North America Veterinary Oncology Market, by Therapy, 2018 - 2030 (USD Million)
  • Table 5 North America Veterinary Oncology Market, by Cancer Type, 2018 - 2030 (USD Million)
  • Table 6 U.S. Veterinary Oncology Market, by Animal, 2018 - 2030 (USD Million)
  • Table 7 U.S. Veterinary Oncology Market, by Therapy, 2018 - 2030 (USD Million)
  • Table 8 U.S. Veterinary Oncology Market, by Cancer Type, 2018 - 2030 (USD Million)
  • Table 9 Canada Veterinary Oncology Market, by Animal, 2018 - 2030 (USD Million)
  • Table 10 Canada Veterinary Oncology Market, by Therapy, 2018 - 2030 (USD Million)
  • Table 11 Canada Veterinary Oncology Market, by Cancer Type, 2018 - 2030 (USD Million)
  • Table 12 Mexico Veterinary Oncology Market, by Animal, 2018 - 2030 (USD Million)
  • Table 13 Mexico Veterinary Oncology Market, by Therapy, 2018 - 2030 (USD Million)
  • Table 14 Mexico Veterinary Oncology Market, by Cancer Type, 2018 - 2030 (USD Million)
  • Table 15 Company Overview
  • Table 16 Service Benchmarking
  • Table 17 Financial Performance
  • Table 18 Strategic Initiatives

List of Figures

  • Fig. 1 North America Veterinary Oncology Market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Information procurement
  • Fig. 4 Primary research pattern
  • Fig. 5 Data Analysis Models
  • Fig. 6 Market Formulation And Validation
  • Fig. 7 Data Validating & Publishing
  • Fig. 8 General methodology for a commodity flow analysis of North America Veterinary Oncology Market
  • Fig. 9 Commodity flow analysis
  • Fig. 10 Parent market analysis
  • Fig. 11 Market snapshot
  • Fig. 12 Segment snapshot
  • Fig. 13 Segment snapshot
  • Fig. 14 Competitive landscape snapshot
  • Fig. 15 Parent market value, 2023 (USD Billion)
  • Fig. 16 Ancillary market outlook, 2023
  • Fig. 17 North America Veterinary Oncology Market Dynamics
  • Fig. 18 Estimated animal population, 2018-2023 by key species and key countries
  • Fig. 19 North America Veterinary Oncology Market: PORTER's analysis
  • Fig. 20 North America Veterinary Oncology Market: PESTEL analysis
  • Fig. 21 North America Veterinary Oncology Market by Animal: Key Takeaways
  • Fig. 22 North America Veterinary Oncology Market by Animal, 2024 & 2030
  • Fig. 23 Canine market, 2018 - 2030 (USD Million)
  • Fig. 24 Feline market, 2018 - 2030 (USD Million)
  • Fig. 25 Equine market, 2018 - 2030 (USD Million)
  • Fig. 26 Horses market, 2018 - 2030 (USD Million)
  • Fig. 27 North America Veterinary Oncology Market by Therapy: Key Takeaways
  • Fig. 28 North America Veterinary Oncology Market by Therapy, Market Share, 2024 & 2030
  • Fig. 29 Radiotherapy market, 2018 - 2030 (USD Million)
  • Fig. 30 Stereotactic Radiation Therapy market, 2018 - 2030 (USD Million)
  • Fig. 31 LINAC market, 2018 - 2030 (USD Million)
  • Fig. 32 Other Stereotactic Radiation Therapy market, 2018 - 2030 (USD Million)
  • Fig. 33 Conventional Radiation Therapy market, 2018 - 2030 (USD Million)
  • Fig. 34 Surgery market, 2018 - 2030 (USD Million)
  • Fig. 35 Chemotherapy market, 2018 - 2030 (USD Million)
  • Fig. 36 Immunotherapy market, 2018 - 2030 (USD Million)
  • Fig. 37 Other therapies market, 2018 - 2030 (USD Million)
  • Fig. 38 North America Veterinary Oncology Market by Cancer Type: Key Takeaways
  • Fig. 39 North America Veterinary Oncology Market by Cancer Type, Market Share, 2024 & 2030
  • Fig. 40 Skin Cancers market, 2018 - 2030 (USD Million)
  • Fig. 41 Lymphomas market, 2018 - 2030 (USD Million)
  • Fig. 42 Sarcomas market, 2018 - 2030 (USD Million)
  • Fig. 43 Other market, 2018 - 2030 (USD Million)
  • Fig. 44 Regional market share analysis, 2024 & 2030
  • Fig. 45 Regional marketplace: Key takeaways
  • Fig. 46 North America Veterinary Oncology Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 Key country dynamics
  • Fig. 48 U.S. Veterinary Oncology Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 Key country dynamics
  • Fig. 50 Canada Veterinary Oncology Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 Key country dynamics
  • Fig. 52 Mexico Veterinary Oncology Market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 Market Participant Categorization
  • Fig. 54 Heat map analysis
  • Fig. 55 Strategic Framework